Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients
Oral Anticoagulant Bleeding Rate and Discontinuation and Adherence Patterns in Non-Valvular Atrial Fibrillation (NVAF) Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Individuals with NVAF who were on warfarin and have switched to the NOACs (dabigatran, rivaroxaban and apixaban) within the study period January 01, 2013 through March 31, 2014
- Individuals ≥18 years old on the index date
- At least 1 year of baseline period with history of continuous warfarin use in the baseline period for at least 3 months immediately before the index date
- At least 1 diagnosis of AF in the 12 months prior to index date
- Continuous eligibility with medical and pharmacy benefits for at least 12 months before the index date through 1 month after the index date
Exclusion Criteria:
- Individuals with a diagnosis of valvular heart disease or cardiac surgery during the 12 months prior to index date
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
patients naive to oral anticoagulant treatment
NVAF patients naïve to oral anticoagulant treatment (Naïve)
|
|
|
patients with prior warfarin therapy
NVAF patients with prior warfarin therapy (Warfarin treated)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Discontinuation rate of patients with prior warfarin use
Time Frame: up to 31 months
|
up to 31 months
|
|
Rate of major bleeding events of patients with prior warfarin use
Time Frame: up to 31 months
|
up to 31 months
|
|
Rate of hospitalization due to major bleeding events of patients with warfarin use
Time Frame: up to 31 months
|
up to 31 months
|
|
Discontinuation rate of patients who were naïve to oral anticoagulant
Time Frame: up to 31 months
|
up to 31 months
|
|
Rate of major bleeding events of patients who were naïve to oral anticoagulant
Time Frame: up to 31 months
|
up to 31 months
|
|
Rate of hospitalization due to major bleeding events of patients who were naïve to oral anticoagulant
Time Frame: up to 31 months
|
up to 31 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Rate of All-Cause Hospitalization
Time Frame: up to 31 months
|
up to 31 months
|
|
Rate of Atrial Fibrillation(AF)-Related Hospitalization
Time Frame: up to 31 months
|
up to 31 months
|
|
Rate of All-Cause Any Rehospitalization
Time Frame: up to 31 months
|
up to 31 months
|
|
Rate of AF-Related Any Rehospitalization
Time Frame: up to 31 months
|
up to 31 months
|
|
Rate of All-Cause Early Hospitalization
Time Frame: up to 31 months
|
up to 31 months
|
|
Rate of AF-Related Early Hospitalization
Time Frame: up to 31 months
|
up to 31 months
|
|
All-Cause Healthcare per patient per month (PPPM) cost
Time Frame: up to 31 months
|
up to 31 months
|
|
AF-related Healthcare per patient per month (PPPM) cost
Time Frame: up to 31 months
|
up to 31 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Heart Diseases
- Cardiovascular Diseases
- Arrhythmias, Cardiac
- Atrial Fibrillation
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Factor Xa Inhibitors
- Antithrombins
- Serine Proteinase Inhibitors
- Anticoagulants
- Rivaroxaban
- Dabigatran
- Apixaban
- Warfarin
Other Study ID Numbers
Other Study ID Numbers
- CV185-412
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.